AC Immune SA
NASDAQ:ACIU
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.29
5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
AC Immune SA
AC Immune SA
PP&E Net
AC Immune SA
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AC Immune SA
NASDAQ:ACIU
|
PP&E Net
CHf5.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
PP&E Net
$16.1m
|
CAGR 3-Years
50%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
PP&E Net
$284.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Molecular Partners AG
SIX:MOLN
|
PP&E Net
CHf4.9m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
PP&E Net
CHf19.4m
|
CAGR 3-Years
73%
|
CAGR 5-Years
28%
|
CAGR 10-Years
4%
|
|
|
Kuros Biosciences AG
SIX:KURN
|
PP&E Net
CHf2.9m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
Glance View
AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
See Also
What is AC Immune SA's PP&E Net?
PP&E Net
5.8m
CHF
Based on the financial report for Sep 30, 2024, AC Immune SA's PP&E Net amounts to 5.8m CHF.
What is AC Immune SA's PP&E Net growth rate?
PP&E Net CAGR 5Y
1%
Over the last year, the PP&E Net growth was -3%. The average annual PP&E Net growth rates for AC Immune SA have been -8% over the past three years , 1% over the past five years .
You don't have any saved screeners yet
